...
首页> 外文期刊>Current opinion in pharmacology >Allosteric modulators of G-protein-coupled receptors.
【24h】

Allosteric modulators of G-protein-coupled receptors.

机译:G蛋白偶联受体的变构调节剂。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Allosteric modulators of G-protein-coupled receptors (GPCRs) interact with binding sites on the receptor that are topographically distinct from the orthosteric site recognized by the receptor's endogenous agonist. Allosteric modulators offer several advantages over standard orthosteric drugs, including the potential for greater receptor subtype selectivity. To date, the current paucity of clinically available allosteric drugs reflects the bias of traditional radioligand binding assays towards the detection of orthosteric effects. However, the advent of new cell-based high-throughput functional assays has led to an increased detection of allosteric GPCR ligands. The current challenge for modulator-based GPCR drug discovery is the optimization of both binding and functional assays to better detect and validate allosteric ligands.
机译:G蛋白偶联受体(GPCR)的变构调节剂与受体上的结合位点相互作用,这些结合位点在地形上不同于受体内源激动剂识别的正构位点。与标准的正构药物相比,变构调节剂具有多个优势,包括具有更大的受体亚型选择性的潜力。迄今为止,当前临床上可用的变构药物的匮乏反映了传统放射配体结合测定法对正构变效应的检测偏向。但是,新的基于细胞的高通量功能测定法的出现导致变构GPCR配体的检测增加。基于调节剂的GPCR药物发现的当前挑战是结合和功能测定的优化,以更好地检测和验证变构配体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号